River Road Asset Management LLC Has $39.62 Million Holdings in Enovis Corporation $ENOV

River Road Asset Management LLC boosted its holdings in Enovis Corporation (NYSE:ENOV) by 3.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,487,277 shares of the company’s stock after purchasing an additional 46,289 shares during the quarter. River Road Asset Management LLC’s holdings in Enovis were worth $39,621,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Arax Advisory Partners bought a new stake in Enovis during the 4th quarter worth approximately $29,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Enovis by 353.5% in the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after purchasing an additional 1,446 shares in the last quarter. Danske Bank A S purchased a new position in shares of Enovis during the third quarter valued at approximately $64,000. Finally, iSAM Funds UK Ltd purchased a new position in shares of Enovis during the third quarter valued at approximately $80,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ENOV. Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. BTIG Research reaffirmed a “buy” rating and set a $39.00 price objective on shares of Enovis in a report on Friday, May 22nd. Evercore reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Enovis in a report on Friday, May 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Finally, Needham & Company LLC increased their target price on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Enovis has a consensus rating of “Moderate Buy” and an average price target of $44.50.

Enovis Stock Performance

Shares of Enovis stock opened at $21.95 on Friday. The business’s fifty day simple moving average is $23.93 and its 200 day simple moving average is $24.32. The firm has a market capitalization of $1.26 billion, a P/E ratio of -1.10 and a beta of 1.38. Enovis Corporation has a 12 month low of $20.55 and a 12 month high of $36.82. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million for the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts anticipate that Enovis Corporation will post 3.65 EPS for the current year.

Insider Activity at Enovis

In related news, insider Oliver Engert purchased 1,200 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, with a total value of $25,944.00. Following the acquisition, the insider owned 51,840 shares of the company’s stock, valued at $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders acquired 4,200 shares of company stock worth $92,084. Insiders own 2.90% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.